News about Clinical Trials

Sanofi's Lunsekimig Shows Promising Phase II Results in Asthma and Nasal Polyps Studies

The novel dual-targeting Nanobody met primary and key secondary endpoints in asthma and chronic rhinosinusitis trials, demonstrating improved outcomes and a favourable safety profile.

Clinical Trials | 08/04/2026 | By News Bureau

CuraTeQ Biologics Announces Positive Phase 3 Results for BP11, Biosimilar to Xolair

CuraTeQ Biologics reports positive Phase 3 results for BP11, a biosimilar to Xolair, meeting primary endpoints in Chronic Spontaneous Urticaria (CSU) studies across Europe and India.

Clinical Trials | 07/04/2026 | By News Bureau |  106

Amgen Announces Positive Phase 3 Results for TEPEZZA

Amgen reports positive Phase 3 topline results for subcutaneous TEPEZZA in thyroid eye disease, with key endpoints met and 77 percent of patients achieving significant proptosis reduction.

Clinical Trials | 07/04/2026 | By News Bureau |  100

Medicus Pharma Submits Phase 2 Protocol to US FDA for Teverelix in Acute Urinary Retention

Medicus Pharma submits Phase 2 protocol to US FDA for Teverelix in acute urinary retention, targeting a USD 2 billion market with a mechanism-driven, capital-efficient development strategy.

Clinical Trials | 07/04/2026 | By News Bureau

Imfinzi Combo Improves PFS in Unresectable Liver Cancer in Phase 3 EMERALD-3 Trial

Imfinzi-based combination improves progression-free survival and shows a trend towards overall survival benefit in unresectable liver cancer in the Phase 3 EMERALD-3 trial.

Clinical Trials | 04/04/2026 | By News Bureau

Merck Initiates Phase 2b/3 Trial of MK-8748 for Neovascular Age-Related Macular Degeneration

Merck initiates a Phase 2b/3 trial of MK-8748 (Tiespectus), a bispecific antibody targeting Tie2 and VEGF pathways for treatment of neovascular age-related macular degeneration.

Clinical Trials | 04/04/2026 | By News Bureau |  150

Vascarta's Curcumin Gel Shows Promising Results in Reducing Osteoarthritis Knee Pain

Clinical trial findings reveal significant pain reduction and strong safety profile for investigational topical gel VAS-101 in adults with knee osteoarthritis.

Clinical Trials | 02/04/2026 | By News Bureau |  494

AskBio Completes Enrollment for Phase 2 Gene Therapy Trial Targeting Heart Failure

The GenePHIT study evaluating investigational therapy AB-1002 for heart failure with reduced ejection fraction has fully enrolled 173 patients, with initial results expected in early 2027.

Clinical Trials | 02/04/2026 | By News Bureau

Alltrna Receives Approval to Begin First-in-Human Trial of tRNA Therapeutic AP003

Alltrna initiates first-in-human trial of engineered tRNA therapy AP003 in Australia, marking a breakthrough in genetic disease treatment.

Clinical Trials | 01/04/2026 | By News Bureau |  221

AviadoBio Advances AVB-101, Starts New Cohort in Phase 1/2 ASPIRE-FTD Trial

AviadoBio advances AVB-101 gene therapy with a new Phase 1/2 ASPIRE-FTD cohort, reporting encouraging early data, securing strategic funding and regaining full programme rights.

Clinical Trials | 01/04/2026 | By News Bureau